Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.52 |
| ▸ | IKZF2 | Q9UKS7 | 4/20 | 0.48 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27315862 | 0.94 | CRBN (0.55) | CRBNIKZF2GSPT1CYP2C19KCNH2 | |
| SCHEMBL27216930 | 0.89 | CRBN (0.55) | CRBNIKZF2IKZF1 | |
| SCHEMBL27315986 | 0.88 | CRBN (0.56) | CRBNIKZF2CSNK1A1IKZF1 | |
| SCHEMBL27217151 | 0.88 | CRBN (0.60) | CRBNIKZF2CSNK1A1IKZF1 | |
| SCHEMBL27217250 | 0.88 | CRBN (0.50) | CRBNIKZF2CSNK1A1IKZF1 | |
| SCHEMBL27317312 | 0.88 | CRBN (0.59) | CRBNIKZF2CSNK1A1IKZF1 | |
| SCHEMBL27317230 | 0.88 | CRBN (0.55) | CRBNIKZF2IKZF1 | |
| SCHEMBL27316988 | 0.88 | CRBN (0.66) | CRBNIKZF2DDB1CSNK1A1IKZF1 | |
| SCHEMBL27322113 | 0.88 | CRBN (0.55) | CRBNIKZF2IKZF1 | |
| SCHEMBL27317308 | 0.88 | CRBN (0.66) | CRBNIKZF2CSNK1A1IKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584259-A1 | CK1ALPHA AND DUAL CK1ALPHA / GSPT1 DEGRADING COMPOUNDS | Innovo Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20240158370-A1 | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| WO-2024054832-A1 | CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054832-A1 | CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158370-A1 | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS | CKS1B, CKS2, MARK1 | CRBN 764/4885IKZF2 4089/4885GSPT1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.